Search

Home > JAMA Network > JAMA Oncology : Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer
Podcast: JAMA Network
Episode:

JAMA Oncology : Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer
Category: Science & Medicine
Duration: 00:17:31
Publish Date: 2016-04-14 10:00:00
Description:

Interview with Ahmad Awada, MD, PhD, author of Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial, and Mark D. Pegram, MD, author of Neratinib in ERBB2-Positive Brain Metastases
Total Play: 0